Clinical Trials Logo

Relapsed, Refractory Melanoma clinical trials

View clinical trials related to Relapsed, Refractory Melanoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02029729 Completed - Clinical trials for Relapsed, Refractory Melanoma

RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER

DISCOVER
Start date: December 31, 2013
Phase: Phase 1
Study type: Interventional

This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are refractory after standard of care therapy for the disease. The results of this study will help provide clinical information for the design and conduct of further clinical studies with RTA 408 in cancer patients.